Brief: Equillium Announces Data From Phase 1B Equip Study In Patients With Uncontrolled Asthma
04/01/2022 14:07
Jan 4 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES DATA FROM PHASE 1B EQUIP STUDY IN
PATIENTS
WITH UNCONTROLLED ASTHMA
* EQUILLIUM INC - ITOLIZUMAB DEMONSTRATED RAPID AND
SUSTAINED
REDUCTION IN LEVELS OF CELL SURFACE CD6
* EQUILLIUM INC - PHASE 1B EQUIP STUDY ACHIEVED PRIMARY
OBJECTIVE
OF SAFETY AND TOLERABILITY
Source text for Eikon: ID:nBwc8BbQMa
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations